Acute Liver Failure Market Size & Share, by Type (Acetyl Cysteine Medications, Liver Transplant, Artificial Hepatic Assist Devices, Hepatocyte Transplantation, Xenotransplantation, Barbiturate Agents); Indications (Encephalopathy and Cerebral Edema, Intracranial Hypertension, Non-Alcoholic Fatty Liver Disease, Acetaminophen Toxicity, Clotting Abnormalities, Renal Failure, Hemorrhage, Metabolic Imbalances) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

Growth Drivers

• Growing Prevalence of Obesity - Improper lifestyle choices and poor eating habits contribute to weight growth, which ultimately results in obesity. In adults, obesity is the primary cause of fatty liver disease, followed by alcoholism. As per a report in 2020, 38% of people worldwide who were five years of age or older were overweight or obese. This percentage is predicted to increase to 51% by 2035. Being overweight or obese causes fat to build up in the liver. This results in persistent inflammation, commonly referred to as cirrhosis, and liver scarring. Fatty liver disease that is not alcoholic is intimately linked to obesity. Excess fat contributes to inflammatory signaling and insulin resistance. Patients with high blood pressure, high cholesterol, obesity, diabetes, or insulin resistance are at an increased risk of developing fatty liver disease. Therefore, the growing incidences of obesity will escalate the growth of the acute liver failure market.
• Increased Geriatric Population Globally – The number of older people at risk of acute liver failure is rising due to global population aging, which is increasing the need for therapies and interventions specific to this population. Chronic liver illnesses, such as non-alcoholic fatty liver disease, are more common in the senior population and can lead to abrupt liver failure if neglected or inadequately managed. Adults also frequently take many drugs to treat different medical issues, which raises the possibility of drug-induced liver damage and possible side effects that could result in abrupt liver failure.
• Increased Technological Advancements in Liver Disease Diagnosis - Technological developments in liver disease detection, such as imaging methods, liver function tests, and digital biomarker-based diagnostics are driving the growth of the acute liver failure market. The accurate assessment and early identification of liver illnesses have improved due to these technological developments. The creation of novel treatment choices that can offer more varied and efficient care, such as immune suppressants, liver transplantation procedures, antiviral medications, and targeted therapies is driving the growth of the market. For instance, Aycan Medical Systems, a provider of radiology informatics, has released Liver Surface Nodularity (LSN), a novel software plugin that diagnoses and stages chronic liver disease. The software, created by Imaging Biometrics, a business partner of Aycan, enables radiologists to anticipate future liver events, assess liver surface nodularity, identify liver illness from normal abdominal CT images, and create a liver score without requiring liver biopsies.

Challenges

• High Costs of the Treatment – Healthcare systems are severely impacted financially by the high expense of the treatment, especially in nations where the healthcare system is publicly funded. Budgets for healthcare may be strained, and resources for other healthcare objectives may be reduced as a result. Lack of insurance coverage may make it financially difficult for individuals to receive acute liver failure therapy, even in nations with developed healthcare systems. Therefore, the high cost of the treatment may hinder the growth of the acute liver failure market.
• Inadequate Healthcare Infrastructure in Developing Countries may Hamper Market Growth
• The Complex Nature of Liver Transplantation may Impede market Growth